Delcath Systems to enter Medicaid National Drug Rebate Agreement

Delcath Systems (DCTH) announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement to expand patient access. Delcath will participate in the Medicaid Drug Rebate Program, which entails providing Medicaid rebates and 340B discounts to eligible entities. The company has initiated the process of entering into the NDRA with the Centers for Medicare and Medicaid Services and expects it to take effect at the beginning of the third quarter of 2025. “Our decision to enter into the NDRA simplifies Medicaid access and enables eligible hospitals to access 340B drug pricing. We believe this will expand treatment availability and accelerate adoption of HEPZATO in the United States,” said Gerard Michel, CEO of Delcath. “Based on current center activation rates and rising utilization, we expect total HEPZATO treatment volume in 2025 to increase at least 200% versus 2024.”